Gene Green

To spur innovation, a manufacturer would have to come to the table with essential human data, data that the drug will work on humans, will be safe and effective on humans.

This antiquated system is overly burdensome and time consuming, and, frankly, doesn't work very well.

The over-the-counter OTC drugs are routinely used to treat a wide variety of ailments.

I think one of the great benefits of the over-the-counter drug industry and the products that our members bring to market is it gives consumers a choice.

The current system also poses challenges for consumer access to potentially better, safer, innovative products.

During the worst of Harvey, the people of Houston and Harris County were able to rely on the dedication of our local TV and radio broadcasters.

The storm dropped 4 feet of rain on greater Houston. Over 100,000 homes and residences were flooded in Harris County alone.

The EPA has been a key Agency responding to Harvey.

Thank you, Mr. Chairman, and thanks to our witnesses for being here this morning.

We are here to discuss the extension of the Special Needs Plans that serve some of our most vulnerable and highest need Medicare beneficiaries.

Since 1965, Medicare has provided affordable health insurance coverage and access to the care for our Nation's seniors.

It is critically important for us to fully consider and appreciate the impact those proposed changes could have on patient safety, health outcomes, and the promotion of value in our healthcare system.

My concern with the two bills we are considering today is that as drafted they would undermine public health, discourage pharmaceutical research, and undermine the FDA's central capacity to ensure medical products used on patients have…

Opening the floodgates for off-label communication puts patients at risk, puts a dent in the armor that ensures patients get effective therapies, and not snake oil.

Broadening off-label communications could erode FDA's approval standard as it would enable the uses of products never found to be safe or effective in patients and weaken consumer confidence in the FDA approval process.

CHIP is designed to sit on top of a strong Medicaid program, and reauthorizing it while simultaneously destroying Medicaid is simply unacceptable.

TrumpCare jeopardizes coverage for millions of kids with Medicaid and CHIP.

Even one child losing coverage in our country is unacceptable. We can do better for our children.

The American Health Center Act, or TrumpCare, guts Medicaid, makes structural changes that would inevitably lead to the rationing of care.

I am disturbed by what the House has done passing TrumpCare, and what the Senate looks like they are poised to do next week.

Funding for both expires at the end of this fiscal year, and timely reauthorization is utterly critical.

H.R. 767, the SOAR to Health and Wellness Act would help healthcare professionals identify and assist human trafficking victims.

It drives more people to go to their physicians and say, 'I have heard these devices are available. Would you help me decide?'

I want to thank the bill sponsors, the FDA, and the broader stakeholder community for their efforts to improve the innovation pipeline and ultimately giving patients access to technologies and therapies that can improve their lives.

I think what we are seeing right now is already, with increased attention paid to hearing loss over-the-counter devices, it is driving people to ask about their hearing.